Greenleaf Trust Sells 72,612 Shares of Stryker Corporation $SYK

Greenleaf Trust reduced its stake in Stryker Corporation (NYSE:SYK) by 0.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,155,933 shares of the medical technology company’s stock after selling 72,612 shares during the quarter. Stryker comprises approximately 42.8% of Greenleaf Trust’s portfolio, making the stock its biggest holding. Greenleaf Trust’s holdings in Stryker were worth $4,173,792,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Amundi lifted its holdings in shares of Stryker by 18.3% in the 2nd quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock worth $392,402,000 after acquiring an additional 192,447 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Stryker by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after buying an additional 65,333 shares during the period. Veritas Asset Management LLP purchased a new stake in shares of Stryker during the second quarter worth about $168,057,000. Bank of America Corp DE purchased a new stake in Stryker in the 2nd quarter worth approximately $1,404,284,000. Finally, Rakuten Investment Management Inc. purchased a new stake in Stryker in the second quarter worth $18,646,000. Institutional investors own 77.09% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Insider Buying and Selling

In related news, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SYK shares. Wells Fargo & Company cut their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Royal Bank Of Canada dropped their price target on Stryker from $420.00 to $375.00 and set an “outperform” rating on the stock in a research report on Friday. Citizens Jmp dropped their price target on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a research note on Friday. Argus set a $370.00 price target on shares of Stryker in a report on Thursday, July 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research note on Thursday. Sixteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $355.84.

Stryker Stock Performance

Shares of NYSE SYK opened at $291.56 on Monday. The firm’s fifty day moving average is $292.83 and its two-hundred day moving average is $324.51. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $389.33. The company has a market cap of $111.83 billion, a P/E ratio of 31.05, a P/E/G ratio of 1.89 and a beta of 0.78. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. Stryker’s quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.19 earnings per share. As a group, analysts anticipate that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a $0.88 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s payout ratio is 37.49%.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.